CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 124 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $5,033,000 | -56.9% | 2,750,000 | -37.1% | 0.02% | -54.3% |
Q1 2022 | $11,671,000 | -57.2% | 4,371,300 | -30.6% | 0.05% | -57.8% |
Q4 2021 | $27,292,000 | -14.9% | 6,303,025 | 0.0% | 0.11% | -22.7% |
Q3 2021 | $32,082,000 | -20.7% | 6,303,025 | -1.4% | 0.14% | -22.5% |
Q2 2021 | $40,473,000 | -17.4% | 6,393,900 | +0.9% | 0.18% | -20.5% |
Q1 2021 | $48,970,000 | +5879.2% | 6,335,000 | +4968.0% | 0.23% | +5625.0% |
Q4 2020 | $819,000 | -90.5% | 125,000 | -87.9% | 0.00% | -92.9% |
Q2 2020 | $8,608,000 | +418.2% | 1,033,406 | +377.2% | 0.06% | +330.8% |
Q1 2020 | $1,661,000 | -72.3% | 216,564 | -70.0% | 0.01% | -59.4% |
Q4 2019 | $5,992,000 | +61.6% | 721,000 | +118.2% | 0.03% | +68.4% |
Q2 2019 | $3,708,000 | -44.9% | 330,498 | -47.2% | 0.02% | -38.7% |
Q1 2019 | $6,726,000 | -69.6% | 625,649 | -57.3% | 0.03% | -71.3% |
Q4 2018 | $22,103,000 | -10.0% | 1,463,796 | +10.2% | 0.11% | +6.9% |
Q3 2018 | $24,563,000 | +579.3% | 1,327,740 | +739.4% | 0.10% | +621.4% |
Q2 2018 | $3,616,000 | – | 158,171 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 524,763 | $7,924,000 | 3.84% |
Congress Park Capital LLC | 123,311 | $1,862,000 | 2.05% |
Perceptive Advisors | 2,911,715 | $43,588,000 | 1.66% |
RTW INVESTMENTS, LP | 908,586 | $13,720,000 | 1.28% |
HAMILTON LANE ADVISORS LLC | 68,753 | $1,038,000 | 0.91% |
HARBOURVEST PARTNERS LLC | 79,193 | $1,196,000 | 0.57% |
SPHERA FUNDS MANAGEMENT LTD. | 273,151 | $4,125,000 | 0.46% |
Exane Asset Management | 50,000 | $755,000,000 | 0.44% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 622,548 | $9,400,000 | 0.38% |
Cormorant Asset Management, LP | 296,712 | $4,480,000 | 0.36% |